In this article, we will discuss the 13 Best Hot Stocks to Buy According to Analysts.

On March 6, Dan Niles, Niles Investment Management founder, joined ‘Power Lunch’ on CNBC to discuss the broader market sell-off and provide a cautious outlook on the current market environment. Addressing the broader sell-off triggered by the conflict involving Iran, Niles emphasized that the primary concern for investors is the duration of the war. While a short-term conflict of less than a month might be manageable, a long-term engagement could drive oil prices above $100, potentially leading to a global recession.

Niles observed a counterintuitive trend where software and the Mag 7 have outperformed since the conflict began. He defended his recent bullish stance on a software rally and noted that even with negative industry commentary and significant AI-driven layoffs, the software index still finished a recent week up 1% while the S&P 500 fell 0.4%. He argued that even if software faces a long-term decline similar to the 2001–2002 period, history shows that such cycles include massive countertrend rallies that can average 14% over two months.

Responding to concerns about market complacency and commodity shortages, Niles asserted that price leads the narrative, meaning that the market’s reaction to news is more telling than the news itself. While his personal belief is that stocks should be lower, he acknowledged that the market is signaling a potential resolution to the conflict. He advised investors to be hyper-selective and to get messy by diversifying into sectors with heavy assets that are less prone to AI-driven obsolescence.

Our Methodology

We used screeners to identify stocks that have gained at least 90% over the past 6 months and had an average upside potential of at least 30%. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: All data was sourced on March 16. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

13 Best Hot Stocks to Buy According to Analysts

13. Praxis Precision Medicines Inc. (NASDAQ:PRAX)

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best hot stocks to buy according to analysts. On February 19, Praxis Precision Medicines reported the financial results for Q4 2025, ending 2025 with $926 million in cash & investments. Following an additional $621 million financing in January, the company’s cash runway is now expected to fund operations into 2028. While R&D expenses rose to $267.1 million for the full year due to intensified clinical activity, the company has also expanded its leadership team and Board of Directors to support its upcoming commercial launches and long-term clinical strategy.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) submitted two NDAs to the FDA for ulixacaltamide, aimed at treating essential tremor, and relutrigine, for specific pediatric epileptic encephalopathies. Both therapies have received Breakthrough Therapy Designation, with ulixacaltamide notably being the first investigational therapy to show positive Phase 3 results for essential tremor.

The company is advancing several high-potential programs through its Cerebrum and Solidus platforms. Vormatrigine, a potent sodium-channel modulator for epilepsy, is expected to yield Phase 3 topline results in Q2 2026, while the antisense oligonucleotide elsunersen is on track for Phase 1/2 results in H1 2026. Beyond its late-stage assets, Praxis Precision Medicines intends to nominate three new development candidates by mid-2026 to address conditions such as autism spectrum disorders and intellectual disabilities, with regulatory submissions planned for the next two years.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for central nervous system/CNS disorders characterized by neuronal excitation-inhibition imbalance in the US.

12. Spruce Biosciences Inc. (NASDAQ:SPRB)

Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s transition toward its next phase of growth. Hooks brings nearly 35 years of biopharmaceutical experience to the role, having overseen 21 new product launches throughout his career. His background includes leadership positions at Reata Pharmaceuticals, where he managed one of the most successful rare disease launches in US history, as well as executive roles at Applied Therapeutics, Clovis Oncology, and Genentech.

The appointment comes as Spruce Biosciences Inc. (NASDAQ:SPRB) prepares for the planned BLA submission for tralesinidase alfa/TA-ERT, an enzyme replacement therapy for Sanfilippo Syndrome Type B/MPS IIIB. The CEO emphasized that Hooks’ expertise in building launch-ready infrastructure and commercial strategy will be critical as the company advances what could be the first disease-modifying treatment for this rare neurological disorder.

In his new role, Hooks will be responsible for shaping the commercial strategy and building high-performing teams to support the potential market entry of TA-ERT. He joins a leadership team currently focused on addressing significant unmet medical needs within the rare disease community.

Spruce Biosciences Inc. (NASDAQ:SPRB) is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.